Abstract Number: L15 • 2018 ACR/ARHP Annual Meeting
The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
Background/Purpose: The diagnostic accuracy of PET/CT against temporal artery biopsy (TAB) in patients suspected of having GCA has not been well studied. PET/CT has traditionally…Abstract Number: L11 • 2018 ACR/ARHP Annual Meeting
Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) such as etanercept (ETN) are often prescribed for psoriatic arthritis (PsA) either alone or in combination,…Abstract Number: L16 • 2018 ACR/ARHP Annual Meeting
Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
Background/Purpose: TPX-100, a peptide derived from Matrix Extracellular Phosphoglycoprotein (MEPE), has been shown to induce articular cartilage regeneration after cartilage injury in animal models. A…Abstract Number: L12 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors
Background/Purpose: TNF inhibitors (TNFi) are recommended for patients with axial SpA (axSpA) who do not respond to or tolerate NSAIDs. Some patients are inadequate responders…Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…Abstract Number: L13 • 2018 ACR/ARHP Annual Meeting
Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
Background/Purpose: Clinical evaluation of efficacy and safety for long-term treatment for ankylosing spondylitis (AS) is important for treatment decision-making. Secukinumab (SEC), a fully human mAb…Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…Abstract Number: L14 • 2018 ACR/ARHP Annual Meeting
Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
Background/Purpose: XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcgRIIb. Co-ligation of CD19 and FcgRIIb inhibits B lineage cells key to SLE…Abstract Number: L19 • 2018 ACR/ARHP Annual Meeting
Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition associated with pain and fatigue, especially during physical activity. Treatments designed to modulate central pain pathways to…Abstract Number: L20 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
Background/Purpose: Tanezumab is a humanized mAb that blocks nerve growth factor (NGF) and is in clinical development for chronic pain treatment. Tanezumab administered intravenously has…Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…Abstract Number: L02 • 2018 ACR/ARHP Annual Meeting
Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy that primarily affects the muscle and skin. In refractory disease, it is common to fail 2 or…Abstract Number: L03 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
Background/Purpose: A previous Phase 2a study of SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, demonstrated positive effects on knee OA pain, physical function,…Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…
ACR Meeting Abstracts